Konstantin Umanskiy to Kaplan-Meier Estimate
This is a "connection" page, showing publications Konstantin Umanskiy has written about Kaplan-Meier Estimate.
Connection Strength
0.035
-
Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission. J Gastroenterol Hepatol. 2019 Dec; 34(12):2090-2095.
Score: 0.035